Ambrogio Orlando
University of Messina
Internal medicineSurgeryRandomized controlled trialIntensive care medicineProspective cohort studyAdverse effectImmunologyColitisVedolizumabInfliximabInflammatory bowel diseaseDiseaseCrohn's diseaseMEDLINEAdalimumabUlcerative colitisIn patientMedicineCohortGastroenterology
Publications 209
#2Jr Fraser Cummings (University of Southampton)
Last. Ambrogio OrlandoH-Index: 35
view all 5 authors...
Introduction null The infliximab biosimilar SB2 was approved in the EU (2016, Flixabi®) and the US (2017, Renflexis®) for the same indications as the reference product (Remicade®) based on a robust analytical and clinical data package. null Areas covered null This systematic literature review summarizes available analytical and clinical data on SB2, including randomized controlled clinical trials and real-world evidence studies. Overall, 184 articles and congress abstracts were identified (exclu...
#1Andrea CostantinoH-Index: 4
#2Daniele Noviello (University of Milan)H-Index: 2
Last. Giammarco MocciH-Index: 13
view all 18 authors...
#1Cristina BezzioH-Index: 11
#2Alessandro ArmuzziH-Index: 58
Last. Chiara Viganò (University of Milano-Bicocca)H-Index: 6
view all 39 authors...
Background: Patients with Inflammatory bowel disease (IBD) are not at high risk of contracting SARS-CoV-2 infection or developing COVID-19 compared to the general population, nor are they at greater risk of negative outcomes. The main risk factors for negative COVID-19 outcomes in IBD patients are older age and comorbidities. The impact of IBD medications on both infection rates and disease severity is unclear. We assessed risk factors for negative outcomes of COVID-19 in IBD patients and used t...
BACKGROUND AND AIM There are few clinical data on Adalimumab (ADA) biosimilars in inflammatory bowel disease. We aimed to perform a multicenter, observational, prospective study on safety and effectiveness of ADA biosimilar ABP 501 in patients with inflammatory bowel disease. METHODS All consecutive patients from the cohort of the Sicilian Network for Inflammatory Bowel Disease treated with ADA biosimilar ABP 501 from February 2019 to February 2020 were enrolled. Patients were divided into three...
#2Alessandro ArmuzziH-Index: 58
Last. Sara Onali (University of Cagliari)H-Index: 2
view all 17 authors...
Abstract null null Inflammatory bowel diseases, namely ulcerative colitis and Crohn's disease, occur worldwide and affect people of all ages, with a high impact on their quality of life. Sex differences in incidence and prevalence have been reported, and there are also gender-specific issues that physicians should recognize. For women, there are multiple, important concerns regarding issues of body image and sexuality, menstruation, contraception, fertility, pregnancy, breastfeeding and menopaus...
#1Federica Crispino (University of Palermo)
#2Mauro Grova (University of Palermo)H-Index: 1
Last. Ambrogio OrlandoH-Index: 35
view all 12 authors...
Objective: There is a growing need for inflammatory biomarkers to predict therapeutic outcome in Crohn's disease (CD) patients.Main outcome measures: The aim was to evaluate whether NLR (neutrophil-to-lymphocyte ratio), PLR (platelet-to-lymphocyte ratio), ELR (eosinophil-to-lymphocyte ratio) and ENLR (eosinophil*neutrophil-to-lymphocyte ratio), could be prognostic biomarkers of endoscopic response (ER) when starting biologics.Research design and methods: Patients with CD who started biologics we...
BACKGROUND Several observational studies on Tofacitinib (TOFA) in ulcerative colitis (UC) have been published over the last 2 years. AIMS To estimate effectiveness and safety of TOFA arising from real-world experience. METHODS PubMed Central/Medline and Embase were systematically searched for real-world observational studies on TOFA for the treatment of UC through November 2020. RESULTS Seven studies comprising 759 patients met the inclusion criteria. The pooled estimate rates were 49% for clini...
During past years, the increasing knowledge of molecular mechanisms of inflammatory bowel disease (IBD) have led to the development of several targeted biological therapies. This great expansion of...
1 CitationsSource
#1Mauro GrovaH-Index: 1
Last. Ambrogio OrlandoH-Index: 35
view all 11 authors...